San Miguel
San Miguel
San Miguel, Lima region, Peru5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 2 | 2026-10-09 | NCT07284459 | |
| A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission | Acute HIV Infection | Recruiting | Phase 2 | 2026-08-18 | NCT05719441 | |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-14 | NCT05878769 | |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Recruiting | Phase 3 | 2026-07-13 | NCT05712200 | |
| Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, chronic obstructive pulmonary disease, hypertensive disorder, lung disorder, obstructive lung disease, pulmonary hypertension, respiratory system disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-05-01 | NCT05612035 |